|
Halozyme Announces Roche Marketing Authorization For MabThera SC For …
MarketWatch SAN DIEGO, March 28, 2014 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced today that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera ® (rituximab) for the treatment of … |
AllAfrica.comGuinea: Development of Antibodies Rushed to Treat Ebola Outbreak in GuineaAllAfrica.comAmid a deadly outbreak of Ebola virus in the western African country of Guinea, an international team of researchers has stepped up production of experi…
|
San Diego’s RuiYi Raises $15M for Pipeline of Biologic Therapeutics
Xconomy San Diego-based RuiYi said has raised $15 million to advance its lead biologic drug candidate in China, and to expand its technology for generating additional monoclonal antibodies that represent a potential new class of biologics for treating a … RuiYi banks $15M from A-list backers to amp up Chinese R&DFierceBiotech DHL Shows that No Business is too Small to Go GlobalJakarta Post |
|
Can AbbVie’s Legacy Products Deliver Further Growth?
Motley Fool … death) being studied in hematologic malignancies, including chronic lymphocytic leukemia; and an experimental new drug treatment offering multifactorial immunomodulatory effects for people with relapsing, remitting multiple sclerosis, called … |
BDliveDevelopment of Antibodies Rushed to Treat Ebola Outbreak in GuineaVoice of AmericaAmid a deadly outbreak of Ebola virus in the western African country of Guinea, an international team of researchers has stepped up production of experimental antib…
Global and China Monoclonal Antibody Industry Report, 2013-2017DigitalJournal.comIn 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche…
Global and China Monoclonal Antibody Industry Report, 2013-2017PR Newswire (press release)In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzum…
) has announced the addition of theVirtual Press Office (press release)In this report, we have analyzed the market opportunity of rituximab biosimilar. Key Topics Covered: 1. Executive Summary 2.Ex-US Experience of Biosimilar launch 3.Introduction – Ri…
Therapy Class Overview: Rituximab biosimilarPR Newswire UK (press release)In this report, we have analyzed the market opportunity of rituximab biosimilar. Key Topics Covered: 1. Executive Summary 2.Ex-US Experience of Biosimilar launch 3.Introduction -…
Therapy Class Overview: Rituximab biosimilarPR Newswire (press release)In this report, we have analyzed the market opportunity of rituximab biosimilar. Key Topics Covered: 1. Executive Summary 2.Ex-US Experience of Biosimilar launch 3.Introduction – Ri…